Clinical and oral characteristics in patients affected by mucopolysaccharidosis type IV – A: Case reports
DOI:
https://doi.org/10.47990/1y1vnc79Keywords:
Mucopolysaccharidoses, Rare diseases, Heredity, Oral manifestations, Glycosaminoglycans.Abstract
Introduction: Mucopolysaccharidoses are rare diseases related to chronic metabolic conditions caused by a genetic mutation that results in the deficiency of lysosomal enzymes responsible for the degradation of glycosaminoglycans, causing alterations in the normal functioning of the organism and oral alterations. Aim: To evaluate the physical, systemic and oral characteristics of two sibling patients with mucopolysaccharidosis type IV-A found in patients treated at the Special Patients Outpatient Clinic of the University of Ribeirão Preto - Unaerp. Cases Report: Clinical Case 1: Female patient, 34 years old; and Clinical Case 2: Male patient, 31 years old. In Clinical Case 1, the following clinical and physical characteristics were observed: respiratory difficulty, bone changes in the arms, valgus deformities of the knees, enlarged thorax, dysostosis with changes in the hands, decreased hearing, rheumatological problems, difficulty in locomotion, changes in motor coordination, short stature, shortened neck and trunk. Regarding oral changes: taurodontia in upper and lower molars, supernumerary tooth, low mandibular height, macroglossia, anterior open bite, vestibular exostoses, dental erosion on the occlusal and palatal/lingual surfaces in almost all teeth, limited mouth opening, atypical swallowing and deep palate. In Clinical Case 2, the same clinical and oral characteristics were observed, except: supernumerary tooth and vestibular exostoses. Conclusion: MPS is a rare disease that affects organs and tissues, requiring lifelong multidisciplinary health treatment, as there is no cure. However, dental treatment is important to contribute to the individual's quality of life.
References
1. Mesquita ACC, Leite EVNC, Neto CM, Oliveira AR, Guedelha LPS, Nunes PLS. Perfil sociodemográfico e clínico de pacientes com mucopolissacaridose em um hospital de São Luís – MA / Sociodemographic and clinical profile in patients with mucopolissacaridose in a hospital in São Luís – MA. Braz. J. Hea. Rev. 2021; 4(3):10996-100.
2. Teodoro JVT, Ribeiro LAB, Ferreira Neto JM, Ferreira VM, Grangueiro, CHP, Oliveira, ANM. Mucopolissacaridoses IV e VI: Aspectos ao Ecocardiograma Bidimensional com Strain pelo Speckle Tracking em uma Série de Casos. Abc., Imagem Cardiovasc. 2021; 34(2): 1- 4.
3. Alencar PHR, Lima KVM, Tourinho EF, Barbosa MSN, Leite CL, Queiroz P dos SS, Nascimento NG da C, Lins GOL, Lopes SMT, Lima Junior FA. Nursing care for patients with mucopolysaccharidosis VI: an integrative literature review. RSD. 2022;1(1):e2211123435.
4. Kubaski F, de Oliveira Poswar F, Michelin-Tirelli K, Burin MG, Rojas-Málaga D, Brusius-Facchin AC, Leistner-Segal S, Giugliani R. Diagnosis of Mucopolysaccharidoses. Diagnostics (Basel). 2020;10(3):172.
5. Hampe CS, Wesley J, Lund TC, Orchard PJ, Polgreen LE, Eisengart JB, McLoon LK, Cureoglu S, Schachern P, McIvor RS. Mucopolysaccharidosis Type I: Current Treatments, Limitations, and Prospects for Improvement. Biomolecules. 2021;11(2):189.
6. Nourbakhsh N, Esfahani EA. "Mucopolysaccharidosis syndrome in a 9-Year-old boy: oral-dental management and diagnostic considerations": a case report. BMC Oral Health. 2024; 27;24(1):1140.
7. Khan SA, Peracha H, Ballhausen D, Wiesbauer A, Rohrbach M, Gautschi M, Mason RW, Giugliani R, Suzuki Y, Orii KE, Orii T, Tomatsu S. Epidemiology of mucopolysaccharidoses. Mol Genet Metab. 2017;121(3):227-240.
8. Poletto E, Pasqualim G, Giugliani R, Matte U, Baldo G. Worldwide distribution of common IDUA pathogenic variants. Clin Genet. 2018;94(1):95-102.
9. Hendriksz CJ, Berger KI, Giugliani R, Harmatz P, Kampmann C, Mackenzie WG, Raiman J, Villarreal MS, Savarirayan R. International guidelines for the management and treatment of Morquio A syndrome. Am J Med Genet A. 2015;167A(1):11-25.
10.Cancino H, Marcela C, Isabel NVS, De Souza MF, Oliveira M. Mucopolysaccharidosis: characteristics and oral changes. RFO UPF. 2016;21(3):395-400.
11. Brasil. Ministério da Saúde. Secretaria de atenção especializada à saúde. Secretaria de ciência, tecnologia e insumos estratégicos. Protocolo Clínico e Diretrizes Terapêuticas da Mucopolissacaridose tipo IV A, 2019.
12. Fecarotta S, Tarallo A, Damiano C, Minopoli N, Parenti G. Pathogenesis of Mucopolysaccharidoses, an Update. Int J Mol Sci. 2020;21(7):2515.
13. Saville JT, Herbst ZM, Gelb MH, Fuller M. Endogenous, non-reducing end glycosaminoglycan biomarkers for the mucopolysaccharidoses: Accurate diagnosis and elimination of false positive newborn screening results. Mol Genet Metab. 2023;140(3):107685.
14. Afonso JCN. Taurodontia: os desafios no tratamento endodôntico não-cirúrgico. 63 f. Tese (Doutorado) - Curso de Ciências da Saúde, Universidade Fernando Pessoa, Porto, 2014.
15. Fardin AC, Gaetti-Jardim EC, Aranega AM, Júnior EGJ, Júnior IRG. Quarto molar retido: a importância do diagnóstico precoce. Revista da Faculdade de Odontologia-Upf, Passo Fundo. 2011;16 (1):90-94.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Latin American Pediatric Dentistry Journal

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.